Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction

A clear consensus does not exist about whether the initial dose of gemcitabine, an essential anticancer antimetabolite, should be reduced in patients with liver dysfunction. Adult patients with biliary tract or pancreatic cancer were divided into three groups according to whether they had mild, mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Takashi, Ebata, Tomoki, Fujita, Ken‐ichi, Shimokata, Tomoya, Maeda, Osamu, Mitsuma, Ayako, Sasaki, Yasutsuna, Nagino, Masato, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768397/
https://www.ncbi.nlm.nih.gov/pubmed/26595259
http://dx.doi.org/10.1111/cas.12851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768397/
https://www.ncbi.nlm.nih.gov/pubmed/26595259
http://dx.doi.org/10.1111/cas.12851

Ejemplares similares